ESG8 Oct 2026, 07:30 pm
Aarti Drugs receives 'Crisil ESG 61 (Strong)' rating
AI Summary
Aarti Drugs Ltd has been assigned an ESG Rating of 'Crisil ESG 61 (Strong)' by Crisil ESG Ratings & Analytic Limited. The rating is based on data pertaining to FY 2025-26 and was received by the company on October 7, 2026. Notably, Crisil ESG Ratings prepared this report independently, without any engagement from Aarti Drugs, utilizing publicly available data.
Key Highlights
- Aarti Drugs assigned 'Crisil ESG 61 (Strong)' rating.
- Rating based on FY 2025-26 data.
- Crisil ESG Ratings prepared the report independently.
- Rating based on publicly available data.
Price Impact
More from AARTIDRUGS